Article Text


069 Systematic review of 1142 admissions with acute heart failure reveals high frequency of transthyretin V122I cardiac amyloidosis in Afro-Caribbean patients
  1. J Dungu1,
  2. M S O'Donnell1,
  3. P N Hawkins2,
  4. L J Anderson1
  1. 1St George's University of London, London, UK
  2. 2National Amyloidosis Centre, UK


Background The genetic mutation encoding transthyretin (TTR) isoleucine 122 (V122I) is present in 3.9% of African-Americans and associated with cardiac TTR amyloidosis, but penetrance is unknown. Little is known about the frequency or clinical phenotype of TTR V122I amyloidosis in the British Afro-Caribbean population.

Methods We reviewed the primary diagnoses of 1142 patients admitted with heart failure between September 2005 and February 2011. The diagnosis was supported by echocardiography, cardiac MRI (in patients without contraindications) and genetic testing; endomyocardial biopsies were performed in 68 patients (6%) in whom amyloidosis was suspected or uncertainty about diagnosis remained. Survival analysis was performed to August 2011.

Results The median age was 72 years (range 18–98) with male (66.7%) and Caucasian (71.0%) predominance. Ischaemic cardiomyopathy (ICM) was the primary diagnosis in 428 patients (37%). There were 170 Afro-Caribbean patients (14.9%) among whom ICM was less common (22 patients (13%), p<0.01). Seventeen Afro-Caribbean patients (10%) were confirmed to have cardiac ATTR V122I amyloidosis. Survival of Afro-Caribbean patients with ICM and ATTR V122I amyloidosis was similar (45 vs 36 months, p=0.54), but overall survival (n=1142) was significantly inferior in cardiac amyloidosis compared to non-amyloid cardiomyopathy (34 vs 59 months, p<0.01).

Conclusion ATTR V122I amyloidosis is an important cause of heart failure in the British Afro-Caribbean population, but it is commonly misdiagnosed as hypertensive cardiomyopathy. Diagnosis requires specialist multidisciplinary investigation including CMR, genetic testing and histology, enabling appropriate management in an era when novel treatments for amyloidosis are entering the clinic.

Abstract 069 Figure 1

Kaplan–Meier curves for all patients (n=1142) demonstrating significantly inferior survival in cardiac amyloidosis compared to non-amyloid cardiomyopathy (p<0.01). Kaplan–Meier curves in Afro-Caribbean patients (N=170) demonstrating no significant difference in survival between ischaemic cardiomyopathy and ATTR V122I (p=0.54).

Abstract 069 Table 1
  • Cardiac amyloidosis
  • heart failure
  • ethnicity

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.